利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

429 条记录 (耗时 0.047 秒)

    METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    2.
    发明申请
    METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE 审中-公开
    治疗慢性阻塞性肺疾病的方法

    公开(公告)号：US20150239989A1

    公开(公告)日：2015-08-27

    申请号：US14632557

    申请日：2015-02-26

    申请人： Clifford G. RISK

    发明人： Clifford G. RISK

    IPC分类号： C07K16/42

    CPC分类号： C07K16/4291 ,  A61K39/39566 ,  A61K2039/505 ,  C07K2317/76 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/862 ,  Y10S530/868

    摘要： The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.

    摘要翻译： 本发明提供了治疗有效量的抗IgE部分治疗具有慢性阻塞性肺疾病（COPD）的哺乳动物，其独立于吸烟状态和哮喘状态。 根据本发明，具有升高的血清IgE水平的COPD患者可受益于所公开的治疗方法。 在某些情况下，已经发现本公开的方法可用于治疗COPD患者，而不管其皮肤试验结果和/或体外对多年生呼吸过敏原的反应性。 根据本发明的抗IgE部分包括但不限于选择性结合给定哺乳动物免疫球蛋白E（例如，人免疫球蛋白E）的任何IgG抗体，例如人源化抗IgE，人源化鼠单克隆抗体和/ 或奥马珠单抗。

    Methods for treating chronic obstructive pulmonary disease
    3.
    发明授权
    Methods for treating chronic obstructive pulmonary disease 有权
    治疗慢性阻塞性肺疾病的方法

    公开(公告)号：US08999339B2

    公开(公告)日：2015-04-07

    申请号：US14298364

    申请日：2014-06-06

    申请人： Clifford G. Risk

    发明人： Clifford G. Risk

    IPC分类号： A61K39/395 ,  C07K16/42 ,  A61K39/00

    CPC分类号： C07K16/4291 ,  A61K39/39566 ,  A61K2039/505 ,  C07K2317/76 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/862 ,  Y10S530/868

    摘要： The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.

    摘要翻译： 本发明提供了治疗有效量的抗IgE部分治疗具有慢性阻塞性肺疾病（COPD）的哺乳动物，其独立于吸烟状态和哮喘状态。 根据本发明，具有升高的血清IgE水平的COPD患者可受益于所公开的治疗方法。 在某些情况下，已经发现本公开的方法可用于治疗COPD患者，而不管其皮肤试验结果和/或体外对多年生呼吸过敏原的反应性。 根据本发明的抗IgE部分包括但不限于选择性结合给定哺乳动物免疫球蛋白E（例如，人免疫球蛋白E）的任何IgG抗体，例如人源化抗IgE，人源化鼠单克隆抗体和/ 或奥马珠单抗。

    Aptameric IgE peptides in a protein scaffold as an allergy vaccine
    4.
    发明授权
    Aptameric IgE peptides in a protein scaffold as an allergy vaccine 有权
    蛋白质支架中的嗜酸性IgE肽作为过敏疫苗

    公开(公告)号：US08865179B2

    公开(公告)日：2014-10-21

    申请号：US12011303

    申请日：2008-01-26

    申请人： Swey-Shen Alex Chen

    发明人： Swey-Shen Alex Chen

    IPC分类号： A61K39/00 ,  G01N33/68 ,  C07K16/42 ,  C07K14/705

    CPC分类号： G01N33/6845 ,  C07K14/70503 ,  C07K16/00 ,  C07K16/4291 ,  C07K2317/50 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2318/00 ,  C07K2318/10 ,  C07K2319/00 ,  C07K2319/60 ,  G01N33/6878 ,  Y10S424/805 ,  Y10S424/81

    摘要： A method is disclosed wherein an antigenic B-cell epitope is discovered by in vitro transcription and translation of pre-determined sequence on thermostable protein scaffolds detected by antibodies to a native protein. Immune reactivities of IgE B-cell epitopes from pre-determined IgE sequences from the constant region, engaged in binding to high affinity IgE Fc receptors, placed in a loop of green fluorescent protein (GFP) were shown immuno-reactive with anti-IgE. Moreover, the antigenic B-cell epitope can be further optimized by molecular evolution, selected by conformer antibody and receptor on solid phase via ribosome display. Alternatively, a random aptameric antigenic sequence inserted into a loop of the protein scaffold, mimicking a pre-determined sequence of a native protein, can be selected by solid phase conformer antibody and receptor via ribosome display. High affinity binding of B-cell epitopes selected from the random aptameric library with antibodies to native pre-determined B-cell epitope of a native protein can be optimized by molecular evolution with error-prone RT-PCR by ribosome display.

    摘要翻译： 公开了一种方法，其中通过抗体对天然蛋白质检测到的耐热蛋白质支架上的预定序列的体外转录和翻译来发现抗原性B细胞表位。 IgE B细胞表位的免疫反应性与来自固定区域的预定IgE序列的免疫反应性（参与与高亲和性IgE Fc受体的结合）置于绿色荧光蛋白（GFP）的环中，显示出与抗IgE的免疫反应性。 此外，可以通过分子进化进一步优化抗原性B细胞表位，通过构象异构体抗体和通过核糖体展示的固相受体选择。 或者，可以通过固相构象异构体抗体和受体通过核糖体显示来选择插入到蛋白质支架的环中的模拟预先确定的天然蛋白质序列的随机适体抗原序列。 选择随机适体文库的B细胞表位与天然蛋白质天然预先确定的B细胞表位的抗体的高亲和力结合可以通过分子进化来优化，通过核糖体显示出现易发生的RT-PCR。

    Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes
    5.
    发明授权
    Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes 有权
    能够结合B淋巴细胞上的人类mIgE的抗C＆amp; mX抗体

    公开(公告)号：US08741294B2

    公开(公告)日：2014-06-03

    申请号：US13888913

    申请日：2013-05-07

    申请人： Academia Sinica

    发明人： Tsewen Chang ,  Jiun-Bo Chen ,  Pheidias C. Wu ,  Alfur F. Hung

    IPC分类号： A61K39/395 ,  C07K16/42

    CPC分类号： C07K16/2803 ,  A61K39/39566 ,  C07K16/4291 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/862 ,  Y10S530/868

    摘要： The invention pertains to the generation and utility of antibodies that can bind effectively to CεmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CεmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of CεmX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of CεmX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.

    摘要翻译： 本发明涉及能够在人B淋巴细胞表面表达的膜结合IgE（mIgE）上有效结合C＆amp; mX结构域的抗体的产生和应用。 已经提出位于人膜结合的ε链上的CH4结构域和C末端膜锚定肽之间的52个氨基酸残基的Cys区域作为用于免疫靶向表达mIgE的B细胞的抗原位点。 目前已经发现，以前报道的，在C细胞C末端结合RADWPGPP（SEQ ID NO：1）肽的单克隆抗体，包括a20，现在已被发现与人B细胞上的mIgE结合不良。 我们已经发现，对于某些片段（例如GLAGGSAQSQRAPDRVL（SEQ ID NO：2）和HSGQQQGLPRAAGGSVPHPR（SEQ ID NO：3））特异性的单克隆抗体，C＆amp; mX可以有效地结合到人B细胞上的mIgE，因此具有效用 用于靶向这些B细胞用于治疗由IgE介导的疾病。

    Methods, compositions and kits relating to chitnases and chitnase-like molecules and inflammation disease
    6.
    发明授权
    Methods, compositions and kits relating to chitnases and chitnase-like molecules and inflammation disease 有权
    方法，组合物和试剂盒涉及chitnases和chitnase样分子和炎症疾病

    公开(公告)号：US08679503B2

    公开(公告)日：2014-03-25

    申请号：US12834650

    申请日：2010-07-12

    申请人： Jack A. Elias ,  Zhou Zhu

    发明人： Jack A. Elias ,  Zhou Zhu

    IPC分类号： A61K39/395 ,  C07K16/40

    CPC分类号： A61K39/395 ,  A61K31/00 ,  A61K31/70 ,  A61K38/12 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/77 ,  C12N9/2442 ,  C12Y302/01014 ,  Y10S424/81 ,  Y10S530/868

    摘要： The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

    摘要翻译： 本发明包括与抑制几丁质酶样分子有关的炎性疾病（例如哮喘，COPD，炎性肠病，特应性皮炎，特应性，过敏，过敏性鼻炎，硬皮病等）的组合物和方法。 本发明还包括鉴定用于治疗炎症性疾病的新化合物的方法，包括但不限于哮喘，COPD等。 这是因为本发明首次证明IL-13和几丁质酶样分子的表达介导和/或与炎性疾病相关，并且抑制几丁质酶样分子治疗甚至预防， 这种病。 因此，本发明涉及抑制几丁质酶样分子治疗和预防炎性疾病的新发现。